Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Alprazolam
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Staccato alprazolam has demonstrated the ability to rapidly terminate seizures in patients with epilepsy in two minutes or less and prevent recurrence of seizure within two hours.
Product Name : Staccato
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 03, 2020
Lead Product(s) : Alprazolam
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alprazolam
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : UCB Pharma S.A
Deal Size : $270.0 million
Deal Type : Acquisition
UCB Acquires Engage Therapeutics for Staccato® Alprazolam
Details : With is acquisition, UCB will have world-wide rights to Staccato[®] Alprazolam and would perform further clinical development, submission, launch and commercialization of Staccato[®] Alprazolam.
Product Name : Staccato
Product Type : Controlled Substance
Upfront Cash : $125.0 million
May 06, 2020
Lead Product(s) : Alprazolam
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : UCB Pharma S.A
Deal Size : $270.0 million
Deal Type : Acquisition